Joel Lexchin

Last updated

Joel Lexchin is a professor emeritus at the York University Faculty of Health where he taught about pharmaceutical policy, an Associate Professor in the Department of Family and Community Medicine at the University of Toronto, an emergency physician at the Toronto General Hospital and a Fellow in the Canadian Academy of Health Sciences. [1] [2] [3] Lexchin is the author of over 160 peer-reviewed publications. [3] [4]

Biography

Lexchin received his MD from the University of Toronto in 1977. [1]

From 1992 for two years Lexchin was a member of the Ontario Drug Quality and Therapeutics Committee. He was the chair of the Drugs and Pharmacotherapy Committee of the Ontario Medical Association from 1997 for two years. [1]

In 2013, he was quoted in a learned article on Drug patents: the evergreening problem, [5] and he wrote the article on the pharmaceutical industry for the Canadian Encyclopedia . [6]

Lexchin is frequently critical of Canada's drug regulator, the Health Products and Food Branch, [7] [8] as has been noticed in the learned press. [9]

In 2006, Lexchin was quoted by Manzer: "Drug approvals are not all science. There’s always decisions to be made around how much risk are we willing to take in terms of drugs, and I think as the industry takes on a larger role in funding the regulatory bodies that those kinds of decisions tend to be made more in favour of the drug companies," [10] and in 2010 was noticed in a Toronto Star article entitled "Health Canada keeps some drug studies secret". [11]

Related Research Articles

Prescription drug list prices in the United States continually are among the highest in the world. The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015. One major reason for high prescription drug prices in the United States relative to other countries is the inability of government-granted monopolies in the American health care sector to use their bargaining power to negotiate lower prices, and the American payer ends up subsidizing the world's R&D spending on drugs.

<span class="mw-page-title-main">Pharmaceutical industry</span> Industry involved with discovery, development, production and marketing of drugs

The pharmaceutical industry is an industry in medicine that discovers, develops, produces, and markets pharmaceutical drugs for use as medications to be administered to patients, with the aim to cure and prevent diseases, or alleviate symptoms. Pharmaceutical companies may deal in generic or brand medications and medical devices. They are subject to a variety of laws and regulations that govern the patenting, testing, safety, efficacy using drug testing and marketing of drugs. The global pharmaceuticals market produced treatments worth $1,228.45 billion in 2020 and showed a compound annual growth rate (CAGR) of 1.8%.

Oxycodone/paracetamol, sold under the brand name Percocet among others, is a fixed-dose combination of the opioid oxycodone with paracetamol (acetaminophen), used to treat moderate to severe pain.

<i>Canadian Medical Association Journal</i> Peer-reviewed general medical journal

The Canadian Medical Association Journal is a peer-reviewed open-access general medical journal published by the Canadian Medical Association. It publishes original clinical research, analyses and reviews, news, practice updates, and editorials.

<span class="mw-page-title-main">Vaccine trial</span> Clinical trial

A vaccine trial is a clinical trial that aims at establishing the safety and efficacy of a vaccine prior to it being licensed.

<span class="mw-page-title-main">Medical research</span> Wide array of research

Medical research, also known as experimental medicine, encompasses a wide array of research, extending from "basic research", – involving fundamental scientific principles that may apply to a preclinical understanding – to clinical research, which involves studies of people who may be subjects in clinical trials. Within this spectrum is applied research, or translational research, conducted to expand knowledge in the field of medicine.

<span class="mw-page-title-main">Varenicline</span> Nicotinic receptor agonist

Varenicline, sold under the brand names Chantix and Champix among others, is a medication used for smoking cessation and for the treatment of dry eye disease. It is a nicotinic receptor partial agonist and a cholinergic agonist. When activated, this receptor releases dopamine in the nucleus accumbens, the brain's reward center, thereby reducing cravings and withdrawal symptoms associated with smoking cessation.

The Health Products and Food Branch (HPFB) of Health Canada manages the health-related risks and benefits of health products and food by minimizing risk factors while maximizing the safety provided by the regulatory system and providing information to Canadians so they can make healthy, informed decisions about their health.

Evergreening is any of various legal, business, and technological strategies by which producers extend the lifetime of their patents that are about to expire in order to retain revenues from them. Often the practice includes taking out new patents, or by buying out or frustrating competitors, for longer periods of time than would normally be permissible under the law. Robin Feldman, a law professor at UC Law SF and a leading researcher in intellectual property and patents, defines evergreening as "artificially extending the life of a patent or other exclusivity by obtaining additional protections to extend the monopoly period."

The Marketed Health Products Directorate (MHPD) is the Canadian federal authority that monitors the safety and effectiveness of health products marketed in Canada. These include:

Established in 2002, the Canadian International Pharmacy Association ("CIPA") is a Canadian association of licensed pharmacy businesses offering mail order pharmacy services to Canadian and international patients. CIPA members sell pharmaceuticals and maintenance medications to individuals upon receipt of a valid prescription. In addition to selling Health Canada approved medications from their licensed Canadian pharmacies, CIPA members also have relationships with regulated international pharmacies and inspected fulfillment centres that directly deliver medications to patients. Patients make the choice from where their medications will be delivered, and this is confirmed with them at time of purchase.

Funding bias, also known as sponsorship bias, funding outcome bias, funding publication bias, and funding effect, refers to the tendency of a scientific study to support the interests of the study's financial sponsor. This phenomenon is recognized sufficiently that researchers undertake studies to examine bias in past published studies. Funding bias has been associated, in particular, with research into chemical toxicity, tobacco, and pharmaceutical drugs. It is an instance of experimenter's bias.

The Journal of Global Drug Policy and Practice describes itself as an open access peer-reviewed public health journal. Critics say it is biased, not peer-reviewed, and not a legitimate scientific journal. It is funded by the US Department of Justice.

Ian Edwin Lawman Hollands Rusted was a Canadian doctor in Newfoundland and Labrador.

Pharmaceutical innovations are currently guided by a patent system, the patent system protects the innovator of medicines for a period of time. The patent system does not currently stimulate innovation or pricing that provides access to medicine for those who need it the most, It provides for profitable innovation. As of 2014 about $140 Billion is spent on research and development of pharmaceuticals which produces 25–35 new drugs annually. Technology, which is transforming science, medicine, and research tools has increased the speed at which we can analyze data but we currently still must test the products which is a lengthy process. Differences in the performance of medical care may be due to variation in the introduction and circulation of pharmaceutical innovations.

<span class="mw-page-title-main">Therapeutics Initiative</span>

The Therapeutics Initiative (TI) is an independent organization at the University of British Columbia (UBC) which researches the effectiveness of medications and provides education to health care providers in British Columbia about the use of medications.

A first-in-class medication is a prototype drug that uses a "new and unique mechanism of action" to treat a particular medical condition. While the Food and Drug Administration's Center for Drug Evaluation and Research tracks first-in-class medications and reports on them annually, first-in-class is not considered a regulatory category. Although many first-in-class medications qualify as breakthrough therapies, Regenerative Medicine Advanced Therapies and/or orphan drugs, first-in-class status itself has no regulatory effect.

James Maskalyk is a Canadian emergency medicine physician, author, and meditation teacher.

Canadian Doctors for Medicare is a Canadian non-profit advocacy organization that was founded in Toronto in 2006. The organization argues against the privatization of healthcare.

References

  1. 1 2 3 "Faculty". York University. Retrieved 3 April 2021.
  2. ↑ "Joel Lexchin MS, MD". Temerty Faculty of Medicine, University of Toronto. Retrieved 3 April 2021.
  3. 1 2 "Technoscience and Regulation Research Unit - Our Team - Joel Lexchin". Department of Pediatrics, Dalhousie University. Retrieved 3 April 2021.
  4. ↑ "Joel Lexchin". scholar.google.com.au. Retrieved 2021-07-19.
  5. ↑ Collier, R. (2013). "Drug patents: The evergreening problem". Canadian Medical Association Journal. 185 (9): E385-6. doi:10.1503/cmaj.109-4466. PMC   3680578 . PMID   23630239.
  6. ↑ "Pharmaceutical Industry". The Canadian Encyclopedia. 4 March 2015.
  7. ↑ Lexchin, Joel (2018). "Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: A retrospective cohort study". BMJ Open. 8 (4): e020377. doi:10.1136/BMJOPEN-2017-020377. PMC   5931291 . PMID   29705760.
  8. ↑ Lexchin, Joel (2019). "Health Canada's Use of its Notice of Compliance with Conditions Drug Approval Policy: A Retrospective Cohort Analysis". International Journal of Health Services. 49 (2): 294–305. doi:10.1177/0020731418821007. PMID   30587064. S2CID   58537973.
  9. ↑ Blouin, D. (2004). "Canada signs agreements to potentially share drug information with the US and Australia". Canadian Medical Association Journal. 171 (2): 121. doi:10.1503/cmaj.1041031. PMC   450348 . PMID   15262871.
  10. ↑ Manzer, Jenny (December 2006). "Taking Care of Business: Up close with Health Canada". Michener Awards Foundation.
  11. ↑ Smith, Joanna (25 November 2010). "Health Canada keeps some drug studies secret". Toronto Star.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.